The market capitalization of Laurus Labs Ltd is 16447.71 crore.
For the last year, ending in March 2022, the company declared a dividend of 100.00% equity, which amounted to Rs. 2 per equity share. For the last 5 years, the company has shown consistency in dividend declaration.
Laurus Labs primary generation of revenue comes out of its synthesis and active pharmaceutical ingredient business operations. These are known as its API businesses, accounting for over 40% of its entire revenue.
In the pharmaceutical sector, Laurus Labs has seen growth with its synthesis business and its active pharmaceutical ingredients business growing 210% and 49%, respectively. This has put the company on a journey of future optimism and development.
In January 2023, the shares of Laurus Labs saw a rise of 5.3%. With a strong boost in demand for its niche businesses that produce the chemicals and other important ingredients required for certain drugs, the future of Laurus Labs looks bright. The company has also made bids for expansion and has shown interest in the purchase of an over 70% stake in Richcore Life Sciences.
The major products that Laurus Labs produces are specific ingredients and chemicals for drugs, and Hepatitis C and oncology drugs.
The company operates from its headquarters in Hyderabad, India, but has manufacturing and research labs at Bangalore and Visakhapatnam, as well as in Hyderabad itself. It also has an R&D center in the USA. It is a multinational corporation and serves a global platform via its subsidiaries in the USA and Europe.
The company holds a good and consistent track record for hanging out dividends, giving them regularly for the past five years.